| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Brian Czerniecki | Q88334128 |
| P2093 | author name string | Cinthia Rosemblit | |
| M. Catherine Lee | |||
| Lucy M. De La Cruz | |||
| Nadia F. Nocera | |||
| P2860 | cites work | Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 | Q24611404 |
| The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology | Q26849519 | ||
| CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful | Q27010682 | ||
| Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy | Q27686800 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer | Q79550106 | ||
| Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer | Q79979044 | ||
| Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice | Q80211173 | ||
| Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model | Q84689704 | ||
| Clinicopathological and prognostic significance of serum cytokine levels in breast cancer | Q87608821 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| The role of regulatory T cells in cancer | Q33631986 | ||
| Antigen-Pulsed CpG-ODN-Activated Dendritic Cells Induce Host-Protective Immune Response by Regulating the T Regulatory Cell Functioning in Leishmania donovani-Infected Mice: Critical Role of CXCL10. | Q33709163 | ||
| CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection | Q33894331 | ||
| Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. | Q34259974 | ||
| Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer | Q34268618 | ||
| HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. | Q34346068 | ||
| CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation | Q34346803 | ||
| The role of HER2 in angiogenesis | Q34437185 | ||
| Antigen-induced T cell death is regulated by CD4 expression | Q34560506 | ||
| HER2/neu in the management of invasive breast cancer | Q34597143 | ||
| Dendritic cell-based vaccines: barriers and opportunities | Q34661797 | ||
| Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest | Q34892977 | ||
| HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies | Q34974436 | ||
| Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 | ||
| The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease | Q35201328 | ||
| A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. | Q35621559 | ||
| Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer | Q35807188 | ||
| Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. | Q35836070 | ||
| HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. | Q35899068 | ||
| Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. | Q35923178 | ||
| CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers | Q36015421 | ||
| Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration | Q36107949 | ||
| Resistance to Trastuzumab in Breast Cancer. | Q36318226 | ||
| Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration | Q36414012 | ||
| Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer | Q36463604 | ||
| Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. | Q36498243 | ||
| Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community | Q36619677 | ||
| Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuv | Q36744405 | ||
| Immunological decision-making: how does the immune system decide to mount a helper T-cell response? | Q36993451 | ||
| Regulatory T cells and tumour immunity - observations in mice and men. | Q37027565 | ||
| Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer | Q37032851 | ||
| CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ. | Q37094941 | ||
| The E75 HER2/neu peptide vaccine | Q37184534 | ||
| HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer | Q37270033 | ||
| Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine | Q37297514 | ||
| Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer | Q37369840 | ||
| Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis | Q37536862 | ||
| Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. | Q37601692 | ||
| Anti-HER2/Neu passive-aggressive immunotherapy | Q37605244 | ||
| HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | Q38301236 | ||
| Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial | Q38407917 | ||
| Better Together: Targeted Combination Therapies in Breast Cancer | Q38651714 | ||
| The immune system and hormone-receptor positive breast cancer: Is it really a dead end? | Q38800892 | ||
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. | Q39130461 | ||
| Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice | Q39176867 | ||
| Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. | Q39320895 | ||
| T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. | Q39666728 | ||
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. | Q40155719 | ||
| Activation-induced cell death limits effector function of CD4 tumor-specific T cells | Q40553904 | ||
| CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. | Q40614121 | ||
| CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes | Q42385826 | ||
| Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 | ||
| PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine | Q42839507 | ||
| Dendritic cell cancer vaccines: from the bench to the bedside | Q42979673 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer | Q43476961 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| T-helper-1-cell cytokines drive cancer into senescence | Q44539245 | ||
| Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. | Q44585173 | ||
| Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. | Q50850972 | ||
| The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. | Q51730682 | ||
| Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. | Q52881463 | ||
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | Q52893849 | ||
| Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. | Q54097743 | ||
| Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. | Q54198584 | ||
| The promise of antibody-drug conjugates. | Q54472969 | ||
| A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. | Q55026341 | ||
| Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma | Q56904280 | ||
| Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes | Q73121354 | ||
| Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity | Q74079764 | ||
| Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance | Q74597422 | ||
| Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach | Q77995528 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 356 | |
| P577 | publication date | 2016-10-06 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention | |
| P478 | volume | 7 |
| Q38648122 | Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ |
| Q47622652 | CD21lo/medCD27+ proinflammatory B cells are enriched in breast cancer patients and promote antitumor T cell responses |
| Q90269095 | Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models |
| Q43760187 | Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer |
| Q90043359 | Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen |
| Q55466488 | Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. |
| Q62604186 | HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy |
| Q93154626 | Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine |
| Q92538988 | The Intriguing History of Cancer Immunotherapy |
| Q49566629 | The dawn of vaccines for cancer prevention |
| Q55240690 | Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. |
| Q58924835 | as a Vector for Cancer Immunotherapy: Current Understanding and Progress |
Search more.